8 completed, 1 terminated, 1 withdrawn. 4 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow Synflorix™: new trials by email Literature Review of Synflorix™ trials Research Report on Synflorix™
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 320 | 2015-06-11 | 2018-08-02 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection Synflorix™ - Infections, Streptococcal, Streptococcus Pneumoniae Vaccines | Phase 3 | Completed | GlaxoSmithKline | 52 | 2013-06-18 | 2019-07-09 |
| Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants Pneumococcal conjugate vaccine GSK2830929A, Pneumococcal conjugate vaccine GSK2830930A, Synflorix™ - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 953 | 2012-07-11 | 2019-07-16 |
| Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers Pneumococcal vaccine GSK2830930A, Synflorix™ - Infections, Streptococcal | Phase 1 | Completed | GlaxoSmithKline | 61 | 2011-12-12 | 2021-02-10 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 454 | 2011-03-04 | 2019-11-27 |
| Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix™ - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 1320 | 2011-02-09 | 2019-06-19 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 391 | 2010-08-18 | 2020-01-21 |
| Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines Nimenrix™, Menjugate®, NeisVac-CTM - Infections, Meningococcal, Meningococcal Vaccines | Phase 3 | Completed | GlaxoSmithKline | 2095 | 2010-07-01 | 2020-12-31 |
| Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines Synflorix™ - Infections, Streptococcal | Terminated | GlaxoSmithKline | 28 | 2010-05-01 | 2016-05-16 | |
| Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine 251154 vaccine, Infanrix hexa™, Synflorix™ - Infections, Rotavirus | Phase 2 | Withdrawn | GlaxoSmithKline | 2010-04-01 | 2015-03-27 |
Haemophilus Infections (6) · Streptococcal Infections (6) · Diphtheria (2) · Poliomyelitis (2) · Tetanus (2) · Hepatitis B (1) · Meningitis (1) · Meningococcal Infections (1) · Otitis Media (1) · Pneumococcal Infections (1) · Pneumonia (1) · Respiratory Tract Infections (1) · Rotavirus Infections (1) · Toxemia (1)
GlaxoSmithKline (10)
Germany (3) · Poland (3) · Spain (2) · Bangladesh (1) · Czechia (1) · Estonia (1) · Philippines (1) · Russia (1) · South Korea (1) · The Gambia (1)
2009 (1)